Loading clinical trials...

CARE Tool Study Aim 3 | Clinical Trials | Clareo Health

NOT_YET_RECRUITINGNA

CARE Tool Study Aim 3

Implement and Evaluate the CARE Tool in a Randomized Trial

NCT07296887•Washington University School of Medicine

Summary

This study is a multi-site randomized trial to study the implementation of the CARE Tool and evaluate the CARE Tool. The CARE Tool is a web-based tool that gives people information about cancer care costs, health insurance, and resources to help with costs. Overall, the study aims to help patients with cancer overcome barriers they face navigating insurance and accessing financial resources.

Eligibility

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

Inclusion Criteria

•\- Members of the cancer care team (e.g., physicians, nurses, research coordinators, financial navigators, social workers) that work with patients receiving treatment for gynecologic, lung, prostate, or colorectal cancer; or members of the billing team and employee of Siteman Cancer Center, Barnes Jewish Hospital, Washington University, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital
•Do not treat patients for gynecologic, prostate, lung, or colorectal cancer
•Age 18 and over
•Primary or recurrent diagnosis of gynecologic, prostate, lung, or colorectal cancer in the last 12 months
•Receiving cancer treatment from Siteman Cancer Center, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital
•Self-reported ability to read and speak English

Exclusion Criteria

•Under the age of 18
•Not diagnosed with gynecologic, prostate, lung, or colorectal cancer within the previous 12 months from recruitment
•Not receiving care at Siteman Cancer Center, Delbert Day Cancer Institute at Phelps Health, or Alton Memorial Hospital
•Cannot give consent due to cognitive or emotional barriers

Locations (3)

Alton Memorial Hospital

Alton, Illinois, United States

Delbert Day Cancer Institute at Phelps Health

Rolla, Missouri, United States

Washington University School of Medicine

St Louis, Missouri, United States

Key Dates

Start Date

April 30, 2026

Primary Completion Date

July 31, 2028

Completion Date

July 31, 2028

Last Updated

March 12, 2026

Enrollment

430

ESTIMATED participants

Conditions

Gynecologic CancerProstate CancerLung CancerColorectal Cancer

Interventions

Financial education information

OTHER

CARE Tool

OTHER

CARE Tool Training

OTHER

Contacts

Ashley Housten, OTD, MSCI, OTR/L

CONTACT

314-454-7958 ahousten@wustl.edu

Krista Cooksey, BA

CONTACT

314-935-7234 kcooksey@wustl.edu

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

NCT07336732

Non-Small-Cell Lung Cancer

View study

RECRUITINGPHASE2

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

NCT05691465

Metastatic Prostate Adenocarcinoma With Neuroendocrine DifferentiationMetastatic Prostate Neuroendocrine Carcinoma+2 more

View study

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: March 12, 2026Data synced to Clareo: March 29, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions

CARE Tool Study Aim 3

Inclusion Criteria

Exclusion Criteria

Andamertinib With or Without Platinum-doublet Chemotherapy Versus Platinum-doublet Chemotherapy in Patients With NSCLC Harboring Atypical EGFR Mutations

Testing the Safety and Effectiveness of Radiation-based Treatment (Lutetium Lu 177 Dotatate) for Metastatic Prostate Cancer That Has Neuroendocrine Cells

Reducing the Incidence of Symptomatic Brain Metastases With MRI Surveillance

Magnetic Resonance Imaging of the Lung: Oncological Applications

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations